Good News! Thiamine dosage study to start soon at San Martino Hospital
Study to identify factors influencing thiamine dosage in high dose thiamine (vitamin B1) therapy for Parkinson's disease
We are very pleased to announce that a priority retrospective study on high dose thiamine has been approved and officially started. The study aims to identify those factors influencing thiamine dosage in high dose thiamine (vitamin B1) therapy and develop a thiamine dosage table, by route of administration, for People with Parkinson’s Disease (PwP).
Study site and Principal Investigator
The site of the study is San Martino hospital, Genoa, Italy. San Martino hospital is a renown Scientific Institute for Research and Healthcare, recognised by the Italian Ministry of Health as an institution of excellence in the field of neuroscience research, including Parkinson’s disease. The Principal Investigator of the study is Dr Roberto Fancellu.
Current challenge: finding the right dose for each
Finding the effective dosage of b1 is one the biggest challenges which people with Parkinsons’ disease, their caregivers and health care providers must meet. The dosage is crucial for the b1 protocol to be effective, as it needs to be tailored to each individual. This is currently done through a trial and error approach, which can make the process at times long and frustrating (https://b1parkinsons.org/finding-the-right-dose ). Having a scientifically determined start dosage for each individual makes b1 therapy more accessible to everybody, increasing the chances of success.
The study has been made possible through the funds raised by the HDT Foundation through the GoFundMe platform, to which many have contributed, including Daphne Bryan, the author of the book “Parkinson’s and The B1 Therapy”. Daphne also administers the Facebook group on the same subject which counts more than 14,000 members to date. Diagnosed with Parkinson’s in 2010, she has been on b1 therapy for 8 years since 2017, living a normal life with no need to change her initial therapy for Parkinson’s until now. Watch the video on her story on our YouTube channel at https://www.youtube.com/watch?v=GvNlmLV3Lqs .
Getting closer to the medical community
This study is preliminary to the randomized, double-blinded, placebo-controlled trial, which aims to determine the safety, dose and efficacy of HDT (B1) therapy in Parkinson’s Disease ( https://b1parkinsons.org/b1-research#two ). Fund-raising is ongoing to support it.
The fact that this scientific study takes place in a prestigious institution is an important event that brings b1 therapy one step closer to the medical community.